| Ytd | -33.35% | |
| 1y | -13.02% |
| Open | 7.24 | Prev Close | 7.33 | Low | 7.24 | High | 7.92 | Mkt Cap | 55.46M |
| Vol | 5.32K | Avg Vol | 16.89K | EPS | -5.86 | P/E | -1.29 | Forward P/E | -0.87 |
| Beta | 1.11 | Short Ratio | 19.96 | Inst. Own | 23.57% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 7.12 | 200-d Avg | 9.45 | 1yr Est | 3.50 |
DRIO News
DarioHealth Corp. (DRIO) Q2 2026 Earnings Call Transcript
DarioHealth NASDAQ: DRIO reported second-quarter 2026 revenue of $5.2 million, down from $5.6 millio
DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.57 per share versus the Zacks Consensu
Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discont
New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare p
Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, Aug. 3, 2026 /PRNews
First commercial offering from Dario's collaboration with Beluga Health adds licensed provider evalu
DarioHealth (DRIO) witnessed a jump in share price last session on above-average trading volume. The
The financing was led by continued support of existing long-term institutional investors along with
DarioHealth (NASDAQ: DRIO - Get Free Report) and Echo Therapeutics (OTCMKTS:ECTE - Get Free Report)
Contract award for over 100,000 eligible employees marks Dario's fifth Fortune 50 client, further re
DarioIQ drives higher engagement and retention, better clinical outcomes, higher client ROI and recu
Agreement representative of Dario's channel-led growth strategy to bring cardiometabolic digital hea
Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Card
Third health plan customer to expand beyond initial deployment, reinforcing Dario's land-and-expand
O'Reilly's extensive experience across healthcare compliance, risk management, regulatory oversight
Dario's best-in-class, consumer-centric chronic care platform, combined now with Beluga's embedded c
DarioHealth (DRIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the
Data from a total of 27 studies presented at ADA over 8 years reinforce Dario's strategic move close
Expansion driven by highly successful partnership based on Dario's consistent ability to engage memb
Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly ear
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterl
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings